Acetaldehyde represents one of the most pharmacologically reactive and biologically consequential intermediate metabolites produced within the mammalian organism following ethanol consumption. While historically dismissed merely as a toxic, transient byproduct responsible for the aversive physiological sequelae of intoxication, contemporary neurobiology and addiction medicine recognize this organic compound as a potent bioactive agent exerting profound actions across hepatic, vascular, and central nervous systems. Understanding the complex toxicokinetics, mutagenic mechanisms, and behavioral pharmacology of acetaldehyde provides foundational insights into the etiology of alcohol use disorders, ethanol-related carcinogenesis, and pharmacological therapeutics.
Acetaldehyde
1. Concise Definition
Acetaldehyde (systematically designated as ethanal) is an organic chemical compound belonging to the aldehyde family with the chemical formula CH3CHO. It is a colorless, highly volatile, and reactive liquid characterized by a pungent, suffocating, fruity odor. In human physiology, it serves primarily as the primary intermediate metabolite of ethanol oxidation, generated via the catalytic action of hepatic alcohol dehydrogenase enzymes.
Beyond its endogenous presence during xenobiotic metabolism, acetaldehyde is ubiquitously synthesized throughout industrial manufacturing processes, tobacco combustion, and microbial fermentation. In clinical and toxicological sciences, it is categorized as a mutagenic electrophile capable of generating stable DNA adducts and protein crosslinks, exerting both profound cytotoxic damage and distinct psychoactive properties within the mesolimbic dopamine pathway.
2. Etymology & Linguistic Origin
The term acetaldehyde derives from a combination of the Latin noun acetum (meaning vinegar or sour wine) and the modern chemical portmanteau aldehyde. The term aldehyde itself was coined in 1835 by the prominent German chemist Justus von Liebig as an abbreviation of the neo-Latin phrase alcohol dehydrogenatus, translating directly to “dehydrogenated alcohol.”
This linguistic construction reflects the empirical chemical observation that the substance is formed when two hydrogen atoms are removed from ethyl alcohol. When Swedish chemist Carl Wilhelm Scheele initially observed the compound in 1774, it was initially conflated with other ether-like derivatives. It was Liebig’s formal identification and linguistic synthesis that anchored “acetaldehyde” within chemical nomenclature, signaling its direct relationship to acetic acid and alcohol oxidation.
3. Pronunciation & Grammatical Form
Phonetically, acetaldehyde is pronounced as /ˌæs.ətˈæl.də.haɪd/ in standard International Phonetic Alphabet (IPA) notation, with primary syllabic stress falling on the third syllable (-al-). In non-specialized phonetic orthography, it is commonly rendered as “as-et-AL-deh-hyde.”
Grammatically, the word functions exclusively as an uncountable singular noun in modern scientific English. Its systematic International Union of Pure and Applied Chemistry (IUPAC) name is ethanal, though acetaldehyde remains the predominant nomenclature across pharmacological, clinical, and physiological literature. Common derivative constructions include adjectival phrases such as “acetaldehyde-derived adducts” and “acetaldehydic condensation products.”
4. Detailed Conceptual Explanation
The conceptual framework governing acetaldehyde centers upon its biological role as a high-affinity electrophilic intermediate positioned midway between ethanol and acetic acid. When an individual consumes beverage alcohol, the molecule undergoes rapid hepatic clearance predominantly mediated by cytosolic alcohol dehydrogenase (ADH) isozymes. ADH oxidizes the hydroxyl group of ethanol into a carbonyl group, yielding acetaldehyde while concurrently converting nicotinamide adenine dinucleotide (NAD+) into its reduced form (NADH). Secondary metabolic routes include the microsomal ethanol oxidizing system (MEOS), dependent on cytochrome P450 2E1 (CYP2E1), and peroxisomal catalase, both of which become particularly active at elevated systemic blood alcohol concentrations.
Once synthesized, acetaldehyde demonstrates profound biochemical reactivity. Under normative physiological conditions, it is extraordinarily short-lived due to the rapid enzymatic intervention of mitochondrial aldehyde dehydrogenase (primarily the ALDH2 isozyme). ALDH2 possesses a remarkably low Michaelis constant (Km) for acetaldehyde, facilitating its near-instantaneous oxidation into non-toxic acetate, which subsequently enters systemic circulation and is converted into acetyl-CoA for the citric acid cycle. However, when ALDH2 activity is pharmacologically inhibited, saturated by massive ethanol ingestion, or genetically compromised, acetaldehyde accumulates rapidly in the blood, tissues, and extracellular fluids.
Unconjugated acetaldehyde possesses an active carbonyl carbon that eagerly attacks nucleophilic residues situated throughout cellular macromolecules, most notably the amino groups of lysine residues in proteins and the exocyclic amino groups of guanine in DNA. In nucleic acids, this nucleophilic attack results in the synthesis of N2-ethylidene-2′-deoxyguanosine and related covalently bound adducts. These lesions disrupt double-helix fidelity, induce chromosomal aberrations, promote sister chromatid exchanges, and impair normal transcription and replication mechanisms. Consequently, the conceptual status of acetaldehyde has shifted over several decades from being understood solely as a metabolic stepping stone to being classified as a definitive Group 1 human carcinogen by the International Agency for Research on Cancer (IARC).
From a neurobiological perspective, acetaldehyde embodies a paradoxical “Janus-faced” pharmacological profile. Peripherally, elevated concentrations elicit intense, adverse autonomic symptoms, including intense facial cutaneous vasodilation, profound hypotension, tachycardia, nausea, headache, and severe emesis—collectively known as the alcohol-flush reaction. Conversely, localized central accumulation of acetaldehyde—either generated in situ via brain catalase and CYP2E1 or traversing the blood-brain barrier under high saturation—demonstrates direct reinforcing, motivational, and anxiolytic actions, acting synergistically with ethanol to establish and maintain addictive behavior.
5. Historical Development
The identification and characterization of acetaldehyde span over two centuries of biochemical and psychiatric investigation:
The initial synthesis of the substance was achieved in 1774 by Swedish-German pharmaceutical chemist Carl Wilhelm Scheele through the chemical oxidation of ethyl alcohol using manganese dioxide and sulfuric acid. Scheele recognized that the resultant vapor exhibited unique volatility and an irritating olfactory profile distinct from ordinary alcohol, though the underlying chemical mechanics remained unresolved.
In 1821, German chemist Johann Wolfgang Döbereiner examined the compound in greater detail through the catalytic contact of ethanol vapor with finely divided platinum black, describing it under the provisional moniker of “light oxygenated ether.” Justus von Liebig resolved its empirical formula in 1835, demonstrating that its synthesis stemmed from the dehydrogenation of ethanol, thereby establishing the moniker acetaldehyde and clarifying its structural place within organic chemistry.
The mid-twentieth century witnessed the convergence of acetaldehyde chemistry with clinical psychiatry and addiction treatment. In 1948, Danish researchers Erik Jacobsen and Jens Hald were investigating the potential anti-helminthic properties of tetraethylthiuram disulfide (disulfiram). Upon consuming moderate amounts of alcohol following exposure to the chemical, they experienced violent physiological malaise, heart palpitations, and intense facial flushing. Subsequent laboratory assays revealed that disulfiram selectively inhibited aldehyde dehydrogenase, causing a massive surge in circulating blood acetaldehyde levels. This accidental discovery gave rise to Antabuse, the first pharmacological aversion therapy approved for alcohol dependence.
During the 1970s and 1980s, geneticists led by Goedde, Harada, and Agarwal uncovered the molecular basis behind the high prevalence of acute alcohol sensitivity observed throughout East Asian populations. Their research identified the ALDH2*2 genetic polymorphism, characterized by a single point mutation that dramatically reduces enzymatic turnover of acetaldehyde. In modern decades, neuroscientists such as Enrico Cherchi, Diana Martinez, and Elio Acquas have documented the central neurochemical effects of acetaldehyde, demonstrating its pivotal contribution to ethanol-induced dopaminergic neurotransmission in the ventral tegmental area.
6. Theoretical Foundations
Several theoretical frameworks explain how acetaldehyde functions across both toxicological and psychological domains:
The Condensation-Tetrahydroisoquinoline (TIQ) Hypothesis: Advanced originally in the early 1970s by researchers such as Virginia Davis and Michael Collins, this hypothesis posited that systemic or central acetaldehyde readily undergoes spontaneous or enzymatically driven Pictet-Spengler condensation with endogenous monoamines. When acetaldehyde condenses with dopamine, it forms salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline). Although initial claims that salsolinol served as an endogenous “opiate-like” driver of physical alcohol addiction faced substantial methodological scrutiny, contemporary neuroscience confirms that salsolinol and related condensation products modulate opioid and dopamine receptors within the ventral tegmental area and nucleus accumbens, functioning as direct neurochemical mediators of alcohol reinforcement.
The Aversive-Reinforcing Balance Model: This psychopharmacological model posits that the biological actions of acetaldehyde operate as a dynamic equilibrium between peripheral aversive feedback and central rewarding sensations. Peripherally, acetaldehyde stimulates capsaicin-sensitive sensory neurons and triggers mast-cell histamine degranulation, inducing immediate autonomic distress that functions as a potent evolutionary deterrent against excessive ingestion. Conversely, central pools of acetaldehyde promote the firing rates of dopamine neurons in the mesolimbic pathway, fostering conditioned place preference and locomotor activation. The likelihood of developing pathological alcohol-seeking behaviors is thus theorized to depend heavily on individual genetic, physiological, and metabolic balances between peripheral aversion and central reinforcement.
Electrophilic Stress and DNA Damage Theory: In cellular pathology and oncogenesis, acetaldehyde acts under the broader theory of electrophilic macromolecular stress. Lacking a balanced clearance mechanism, reactive electrophiles deplete cellular glutathione reserves, destabilize cellular redox potential, disrupt mitochondrial respiration, and induce extensive cross-linking between histones and nuclear DNA. When DNA repair pathways (specifically the Fanconi anemia crosslink repair pathway) are compromised, these lesions result in permanent chromosomal translocations and point mutations, promoting the initiation and progression of aerodigestive cancers.
7. Key Components, Types & Dimensions
To fully evaluate the pharmacology and toxicity of acetaldehyde, several biological components, metabolic routes, and chemical dimensions must be delineated:
- Metabolic Enzymatic Pathways:
- Alcohol Dehydrogenase (ADH): Cytosolic metalloenzymes converting ethanol into acetaldehyde via NAD+ reduction; includes high-activity variants such as ADH1B and ADH1C.
- Cytochrome P450 2E1 (CYP2E1): An inducible microsomal enzyme that oxidizes ethanol into acetaldehyde while generating significant reactive oxygen species (ROS), central to chronic heavy drinking pathology.
- Peroxisomal Catalase: A primary enzyme mediating the oxidation of ethanol to acetaldehyde within central brain tissue utilizing hydrogen peroxide.
- Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2): The primary high-affinity enzyme responsible for metabolizing acetaldehyde into non-toxic acetate.
- Macromolecular Adduct Formations:
- Unstable Schiff Bases: Reversible initial adducts formed between the carbonyl carbon of acetaldehyde and primary amine groups of amino acids and basic proteins.
- Stable Malondialdehyde-Acetaldehyde (MAA) Adducts: Irreversible hybrid adducts that alter protein antigenicity and trigger robust proinflammatory and fibrotic autoantibody responses, especially within hepatic stellate cells.
- Deoxyguanosine DNA Adducts: Stable chemical modifications (e.g., N2-ethylidene-dG) that induce structural distortion in the genetic code, fostering replication errors and oncogenesis.
- Physiological Compartmentalization:
- Peripheral Systemic Pool: Circulating acetaldehyde within the bloodstream and visceral organs, driving autonomic distress, vasodilation, and hepatic clearance.
- Central Nervous System Pool: Acetaldehyde synthesized in situ within astroglial cells and neural structures, mediating psychoactive, reinforcing, and anxiolytic actions.
8. Examples & Illustrative Cases
Clinical Case 1: The Disulfiram Pharmacotherapy Challenge: A 44-year-old male presenting with severe alcohol use disorder commences treatment with oral disulfiram (250 mg daily). Four days into the regimen, the patient consumes approximately 30 mL of ethanol. Within ten minutes, disulfiram’s irreversible inhibition of mitochondrial ALDH2 causes circulating blood acetaldehyde levels to rise five- to ten-fold above baseline intoxicating thresholds. The patient experiences sudden facial flushing, throbbing cephalalgia, severe nausea, orthostatic hypotension, dyspnea, and profound subjective terror. The immediate distress of this disulfiram-ethanol reaction serves as a pharmacologically induced conditioned aversion, reinforcing behavioral abstinence through the psychological dread of acute acetaldehyde toxicity.
Clinical Case 2: The ALDH2*2 Polymorphic Deficiency: A 22-year-old female of East Asian descent consumes half a glass of red wine at a social gathering. Within fifteen minutes, she presents with intense cutaneous erythema across her face, neck, and shoulders, accompanied by sinus tachycardia (heart rate exceeding 115 beats per minute) and dizziness. Genomic analysis demonstrates heterozygosity for the ALDH2*2 allele (Glu504Lys point mutation), which renders her ALDH2 enzyme with only roughly 6% to 10% of normal catalytic turnover capacity. The acute accumulation of unmetabolized acetaldehyde produces substantial peripheral vasodilation and cardiac output redistribution, rendering further alcohol consumption aversive and drastically decreasing her epidemiological risk of developing alcoholism while simultaneously increasing her long-term esophageal cancer vulnerability if exposed to sustained chronic intake.
9. Measurement & Assessment
The quantification of acetaldehyde in biological matrices poses significant technological challenges due to its extreme volatility (boiling point approximately 20.2°C), its rapid binding to erythrocytes, and the persistent risk of artificial artifactual formation via non-enzymatic spontaneous oxidation of residual ethanol during assay preparation.
The gold standard for biomedical and toxicological evaluation involves Headspace Gas Chromatography coupled with Mass Spectrometry (HS-GC-MS) or Flame Ionization Detection (HS-GC-FID). Biological specimens (such as whole blood, plasma, or tissue homogenates) must be immediately preserved with protein-precipitating agents—such as perchloric acid (PCA)—and cooled under strict cryogenic conditions to halt ongoing enzymatic reactions and break reversible hemoglobin adducts. Specialized derivatization agents, including 2,4-dinitrophenylhydrazine (DNPH) or o-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine (PFBHA), are frequently introduced to form stable hydrazone or oxime conjugates, facilitating robust gas-chromatographic separation and nanogram-level detection sensitivity.
In epidemiological and occupational health contexts, alternative markers evaluate downstream biological footprints rather than volatile free acetaldehyde. Clinicians and researchers measure circulating anti-MAA (malondialdehyde-acetaldehyde) antibodies or employ liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify urinary concentrations of N2-ethylidene-2′-deoxyguanosine. These stable biomarkers provide longitudinal windows into chronic tissue exposure, oxidative stress, and ongoing cellular mutagenesis.
10. Applications & Practical Significance
Understanding the properties of acetaldehyde yields substantial applications across multiple scientific and medical arenas:
Addiction Pharmacotherapy: Pharmacological manipulation of the acetaldehyde metabolic cascade constitutes a foundational paradigm in aversion therapy. In addition to disulfiram, agents like calcium carbimide function through reversible ALDH inhibition. Modern drug development programs investigate selective brain catalase inhibitors and sequestration agents (e.g., L-cysteine and D-penicillamine) capable of binding central acetaldehyde directly, thereby dampening ethanol’s reinforcing neuropharmacological properties without triggering systemic toxicity.
Oncology and Risk Stratification: Given the mutagenic profile of acetaldehyde, clinical oncology utilizes ALDH2 genotyping as a screening tool. Individuals harboring the inactive ALDH2*2 variant who persist in moderate to heavy drinking exhibit up to a ten-fold elevated relative risk for esophageal squamous cell carcinoma and upper aerodigestive tract malignancies compared to wild-type counterparts. Public health campaigns leverage this knowledge to promote early lifestyle interventions and targeted endoscopic screening protocols.
Occupational Safety and Industrial Hygiene: Acetaldehyde is produced industrially on a multi-ton scale as a chemical intermediate for the synthesis of acetic acid, pyridine derivatives, pentaerythritol, and synthetic resins. It is also an abundant component of automobile exhaust and environmental tobacco smoke. The Occupational Safety and Health Administration (OSHA) and the National Institute for Occupational Safety and Health (NIOSH) establish strict permissible exposure limits (PEL) to prevent acute mucosal and pulmonary epithelial damage, chronic respiratory impairment, and occupational carcinogenesis in factory environments.
11. Research & Empirical Evidence
Pioneering investigations by Quertemont, Tambour, and colleagues (2005) reshaped the neuropharmacological consensus regarding alcohol addiction by demonstrating that central administration of acetaldehyde directly induces motor stimulation and conditioned place preference in rodent models, even when ethanol metabolism is completely inhibited. Their studies verified that central acetaldehyde possesses intrinsically rewarding neurochemical properties distinct from unoxidized ethanol.
Furthering these mechanistic discoveries, Diana, Martinez, and Acquas demonstrated that localized microinjections of acetaldehyde directly into the ventral tegmental area (VTA) markedly elevate extracellular dopamine release within the nucleus accumbens shell. This effect is mediated via the opening of hyperpolarization-activated cyclic nucleotide-gated (HCN) pacemaker channels and secondary interaction with nicotinic acetylcholine receptors. Intriguingly, when central catalase activity is experimentally knocked down, the locomotor and dopamine-releasing capabilities of low-dose ethanol are substantially attenuated, confirming that central bio-transformation of ethanol into acetaldehyde is required for several key aspects of ethanol-induced euphoria.
In oncology, large-scale epidemiological investigations led by Philip J. Brooks at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) definitively documented that acetaldehyde-derived DNA damage is the direct mechanistic cause of elevated upper aerodigestive tract cancers in alcohol-exposed populations with ALDH2 deficiencies. His longitudinal genomic studies demonstrated that chronic exposure leads to pervasive G-to-A transition mutations and transversion anomalies in oncogenes and tumor suppressor genes such as TP53.
12. Cultural & Cross-Cultural Considerations
The cultural dynamics of ethanol consumption and alcohol-related toxicity are deeply intertwined with geographic variations in acetaldehyde-metabolizing enzymes. The most prominent example is the distribution of the ALDH2*2 (rs671) allele, often referred to colloquially in cross-cultural dialogues as the source of the “Asian flushing syndrome.” This genetic variant is concentrated predominantly in East Asian populations—present in approximately 30% to 50% of individuals of Chinese, Japanese, and Korean descent—while being virtually absent in native African, European, and indigenous South American ancestries.
Anthropological and evolutionary studies propose that the ALDH2*2 allele originated among the ancient Han Chinese population in the Yangtze River valley thousands of years ago, potentially persisting due to natural selection pressures against parasitic infections or by acting as a protective barrier against endemic alcohol abuse. In contemporary East Asian cultures, the physical presence of the flush reaction carries complex social connotations. In business and social dining environments where ritual drinking is common, individuals possessing the variant face distinct health hazards if cultural pressures override their natural physiological aversion, driving elevated risks of esophageal cancer and hypertension.
Conversely, in cultures where high-activity ADH1B variants (e.g., ADH1B*2) are common, ethanol is converted into acetaldehyde at exceptionally rapid rates, reinforcing an inherent biological resistance to sustained alcohol consumption. These broad genomic variations highlight the necessity for culturally competent medical counseling regarding drinking habits, health screening, and personalized risk profiling.
13. Criticisms, Debates & Limitations
Despite robust empirical validation, several enduring debates and methodological limitations persist within acetaldehyde research:
The Blood-Brain Barrier Controversy: A longstanding point of scientific contention is whether peripherally generated acetaldehyde can cross the blood-brain barrier (BBB) under ordinary drinking conditions. The microvascular endothelial cells constituting the BBB possess exceptionally high levels of ALDH2, forming an enzymatic barrier that metabolizes circulating acetaldehyde before it can penetrate neural parenchyma. Skeptics argue that physiological blood acetaldehyde concentrations measured during normal intoxication are insufficient to breach this barrier, leading critics to question the clinical relevance of peripheral acetaldehyde to central subjective reward. However, counter-theories emphasize that high concentrations can saturate endothelial ALDH2, or that in situ enzymatic generation directly within brain astrocytes by catalase bypasses the barrier entirely.
Artifactual Generation in Analytical Chemistry: A major technical criticism levied against older literature pertains to the analytical artifact problem. When blood samples containing high concentrations of ethanol are processed at room temperature, even trace amounts of oxyhemoglobin can oxidize ethanol non-enzymatically into acetaldehyde ex vivo. As a consequence, many historical studies from the 1970s and 1980s published massively inflated systemic acetaldehyde levels, distorting clinical hypotheses regarding its physiological concentrations during normal intoxication.
The Validity of the Salsolinol Paradigm: While salsolinol formation from acetaldehyde and dopamine is biochemically verified in vitro, critics maintain that endogenous levels detected in human cerebrospinal fluid and brain tissue remain far too low to account entirely for alcohol dependence. Opponents suggest that focusing on salsolinol overstates the relevance of condensation products while underestimating ethanol’s direct molecular interactions with gamma-aminobutyric acid (GABA-A) receptors, glutamate receptors, and cell membrane channels.
14. Related Terms & Distinctions
Acetaldehyde must be carefully differentiated from closely related chemical intermediates, precursors, and physiological metabolites:
- Ethanol (Ethyl Alcohol): The psychoactive dietary precursor; a two-carbon aliphatic alcohol that acts primarily as a central nervous system depressant via allosteric modulation of GABA-A and NMDA receptors, whereas acetaldehyde is its immediate, highly reactive, electrophilic carbonyl metabolite.
- Acetic Acid (Acetate): The downstream, non-toxic metabolic product of acetaldehyde oxidation catalyzed by ALDH2; an organic acid utilized by peripheral muscle tissue and brain cells for energy generation through conversion into acetyl-coenzyme A.
- Formaldehyde: A simpler, single-carbon aldehyde (HCHO) derived from methanol metabolism; significantly more toxic, neurodegenerative, and blinding than acetaldehyde, rapidly producing severe metabolic acidosis and optic nerve destruction.
- Salsolinol: A complex tetrahydroisoquinoline alkaloid formed specifically through the chemical condensation of acetaldehyde with the neurotransmitter dopamine; distinct from free, uncomplexed acetaldehyde.
- Disulfiram: A pharmaceutical ALDH inhibitor designed to halt the clearance of acetaldehyde, creating an intentional, therapeutic elevation of the substance in vivo.
15. Summary / Key Takeaways
Acetaldehyde is an indispensable, chemically reactive intermediate that sits at the center of ethanol metabolism, systemic toxicology, and neurobiology. While mitochondrial ALDH2 normally eliminates the compound through rapid conversion into acetate, enzymatic deficiencies or saturation lead to substantial cellular and physiological consequences. Peripherally, accumulated acetaldehyde evokes a potent autonomic flush reaction that serves as an innate deterrent against alcohol misuse, yet chronically exposes epithelial cells to mutagenic DNA adducts that elevate cancer risks. Centrally, the compound acts in concert with dopamine systems to mediate reinforcement, highlighting its status as both an adverse toxicological agent and an active neuropharmacological driver of addiction pathology.
References
- Brooks, P. J., & Zakhari, S. (2014). Moderate alcohol consumption and cancer: The role of acetaldehyde. Alcoholism: Clinical and Experimental Research, 38(12), 2891–2894. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4273874/
- Correa, M., Salamone, J. D., Segovia, K. N., Pardo, M., Longoni, R., Spina, L., Peana, A. T., Vinci, S., & Acquas, E. (2012). More than one ‘drink’ of acetaldehyde: What have we learned from its behavioral effects? Pharmacology Biochemistry and Behavior, 100(4), 817–827. https://pubmed.ncbi.nlm.nih.gov/22008745/
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. (2012). Personal habits and indoor combustions: Acetaldehyde associated with consumption of alcoholic beverages. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 100E, 377–400. https://publications.iarc.fr/122
- National Center for Biotechnology Information. (2024). PubChem Compound Summary for CID 177: Acetaldehyde. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Acetaldehyde
- Quertemont, E., & Didone, V. (2006). Role of acetaldehyde in mediating the pharmacological and behavioral effects of alcohol. Alcohol Health and Research World, 29(4), 258–265. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527027/